FDA updates EUA for COVID-19 convalescent plasma

The Food and Drug Administration last week revised and reissued its emergency use authorization for COVID-19 convalescent plasma to treat hospitalized patients with COVID-19.

The changes include updates based on additional clinical trials; clarify the authorization’s limit to high-titer convalescent plasma for hospitalized patients early in the disease and those with impaired humoral immunity; and add to the tests acceptable for qualifying high-titer COVID-19 convalescent plasma.